人HUT78细胞褪黑素受体的基因与蛋白表达的研究

为了检测人HUT78细胞是否存在褪黑素受体(melatoninreceptor,MR)及其亚细胞分布特点 ,采用异硫氢酸胍 苯酚 氯仿一步法抽提总RNA ,进一步通过RT PCR方法检测MR亚型mt1和MT2 的mRNA ,并将RT PCR的阳性产物通过自动测序仪测序 ;同时应用免疫组化染色方法检测mt1和MT2 受体亚型蛋白在HUT78细胞内的分布特点。RT PCR方法则得到了 3 68bpmt1cDNA片段 ,无 3 2 1bpMT2 cDNA片段 ,同时将mt1阳性条带通过胶回收、测序 ,结果显示扩增产物与人mt1受体亚型的基因序列相吻合 ;免疫组化结果显示 ,人HUT78细胞存在mt1受体蛋白 ,主要分布于细胞膜和细胞浆 ,呈棕褐色阳性颗粒 ,而细胞核上未见阳性颗粒 ,MT2 受体蛋白则未检出。提示褪黑素 (melatonin,Mel)对T淋巴细胞具有直接调节作用 。

下丘脑褪黑素受体亚型基因及蛋白表达的研究(英文)

目的 :应用 PT- PCR技术和免疫组织化学染色显示人胚胎下丘脑褪黑素受体及其亚型的分布。方法 :取人胚胎下丘脑组织 ,抽提总 RNA并应用 RT- PCR方法检测其 m RNA,扩增所得阳性产物用自动测序仪测序 ;石蜡包埋下丘脑组织 ,应用鼠抗人 m t1 和 MT2 受体单克隆抗体分别检测褪黑素 mt1 和 MT2 受体亚型 m RNA及其蛋白的表达。结果和结论 :人胚胎下丘脑组织中存在 m t1 和 MT2 受体亚型 m RNA的表达及其蛋白的翻译 ,提示在该组织中有 m t1 和 MT2

Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate Cancer

Objective: The molecular mechanism of prostate cancer is poorly understood. The aim of the study was to investigate the prevalence and prognostic value of promoter hypermethylation of retinoic acid receptor beta (RARB) and p16 among benign prostatic hyperplasia (BPH) and prostate cancer patients. Methods: In this case-control study, 63 patients were included in three groups; 21 with BPH as the control group, 21 with prostate cancer and good prognostic factors (based on prostate-specific antigen, Gleason score and stage) as good prognosis group, and 21 with prostate cancer and poor prognostic features as poor prognosis group. The prostate biopsy specimen of each individual was examined for hypermethylation of RARB and p16 promoters by methylation specific PCR (MSPCR). Results: Seven (33.3%) patients with good prognosis and 15 (71.4%) patients with poor prognosis were positive for RARB methylation, which were significantly higher than controls (P <0.0001). p16 promoter methylation was shown in 19.0% and 47.6% patients with good and poor prognosis, respectively. The RARB and p16 promoter methylation in the poor prognosis group was significantly higher than that in the good prognosis group (P =0.02 for RARB and P<0.0001 for p16). Conclusion: Hypermethylation of RARB and p16 promoters may predict prognosis in prostate cancer.

DHCC受体的纯化

本文报告了正常雄性家兔小肠粘膜细胞核提取液,经 38％饱和废硫酸铵沉淀、DEAE-纤维素层析、DNA-纤维素层析、羟基磷灰石层析、Sephadex G—200凝胶过滤,最终得到纯化5200倍的DHCC受体40μg,产率为9％。

PD-1单抗联合微波消融治疗原发性肝癌的临床疗效

[目的]探讨程序性死亡蛋白1(PD-1)单抗联合微波消融治疗原发性肝癌的临床疗效.[方法]回顾性分析2019年1月至2020年10月本院收治的78例原发性肝癌患者的临床资料,根据治疗方法的不同将其分为联合组(予以PD-1单抗联合微波消融治疗)和对照组(单一微波消融治疗),每组39例.比较两组患者的临床疗效、免疫功能、不良反应,采用Kaplan-M eier分析患者生存率.[结果]联合组疾病控制率及客观缓解率均高于对照组,差异有统计学意义(P<0.05).治疗后,两组患者CD39^(+)、CD73^(+)水平均低于治疗前,且联合组均低于对照组(P<0.05).联合组皮疹发生率高于对照组,差异有统计学意义(P<0.05);两组其他不良反应发生情况比较,差异无统计学意义(P>0.05).两组总生存率曲线比较,差异有统计学意义(P<0.05).[结论]PD-1单抗联合微波热消融治疗原发性肝癌患者,有助于提高患者疾病控制率,延长患者生存期且具有一定的安全性.